IASO Biotechnology and Innovent Biologics, Inc. announced that China National Medical Products Administration has approved the New Drug Application for FUCASO, the world’s first fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent.
